Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has provided an announcement.
Chimeric Therapeutics has advanced its CHM CDH17 clinical trial to dose level 2, administering 150 million CDH17 CAR-T+ cells, with early results showing anti-tumor activity and no new safety concerns. This progress in their Phase 1/2 trial, targeting advanced colorectal, gastric, and intestinal neuroendocrine tumors, marks a significant step in their efforts to develop a novel CAR-T cell therapy, potentially impacting their market positioning and offering new hope for patients with these challenging cancers.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics is a clinical stage cell therapy company based in Australia, recognized as a leader in the cell therapy industry. The company focuses on developing innovative cell therapies for cancer treatment, with a diversified portfolio that includes autologous CAR T cell therapies and allogeneic NK cell therapies. Their assets are being developed across multiple oncology areas, with four clinical stage programs currently underway.
Technical Sentiment Signal: Sell
Current Market Cap: A$11.37M
For a thorough assessment of CHM stock, go to TipRanks’ Stock Analysis page.